Clinical Trial Update: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine with combination chemotherapy in infants with KMT2A-rearranged acute lymphoblastic leukemia and related ambiguous-lineage l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Leukemia of Ambiguous Lineage
• Mixed Phenotype Acute Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Combination chemotherapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-10-26